CC
VRTX icon

Corton Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Corton Capital’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,278
Closed -$515K – 425
2024
Q4 		$515K Buy
+1,278
New +$592K 0.3% 12
2024
Q3 		– Sell
-613
Closed -$287K – 676
2024
Q2 		$287K Sell
613
-2,109
-77% -$915K 0.15% 211
2024
Q1 		$1.14M Buy
2,722
+733
+37% +$310K 0.42% 23
2023
Q4 		$809K Buy
1,989
+713
+56% +$263K 0.26% 75
2023
Q3 		$444K Sell
1,276
-701
-35% -$245K 0.22% 119
2023
Q2 		$696K Buy
1,977
+143
+8% +$48.2K 0.33% 56
2023
Q1 		$578K Buy
1,834
+1,038
+130% +$311K 0.4% 39
2022
Q4 		$230K Buy
+796
New +$243K 0.19% 184
2022
Q3 		– Sell
-1,299
Closed -$366K – 377
2022
Q2 		$366K Sell
1,299
-1,364
-51% -$365K 0.35% 103
2022
Q1 		$695K Buy
+2,663
New +$632K 0.3% 62

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Corton Capital's VRTX Position: Q1 2025 in Review

Corton Capital sold out of Vertex Pharmaceuticals (VRTX) in Q1 2025, closing a stake of 1,278 shares — an estimated $515K sold.

Corton Capital first reported a position in VRTX in Q1 2022 and held it in 10 quarters. The position peaked at $1.14M in Q1 2024. 1,616 funds tracked by Wall St. Rank hold VRTX as of Q1 2025.

  • Corton Capital reported no remaining Vertex Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Corton Capital sold 1,278 Vertex Pharmaceuticals shares in Q1 2025, an estimated $515K.
  • Corton Capital first reported a position in Vertex Pharmaceuticals in Q1 2022 and held it in 10 quarters.
  • Corton Capital's Vertex Pharmaceuticals position peaked at $1.14M in Q1 2024.
  • 1,616 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2025.

Based on Corton Capital's 13F filing for Q1 2025, filed 7 May 2025.